XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net Revenue $ 13,044,571 $ 5,823,942 $ 30,526,572 $ 17,110,511
Cost of goods sold 2,228,561 517,611 3,991,728 1,528,449
Gross profit 10,816,010 5,306,331 26,534,844 15,582,062
Operating expenses        
Selling, general and administrative expenses 12,062,195 6,920,105 31,865,958 18,891,979
Research and development 1,061,387 35,674 2,333,024 257,867
Depreciation and amortization 814,881 204,570 1,556,752 395,968
Total operating expenses 13,938,463 7,160,349 35,755,734 19,545,814
Operating loss (3,122,453) (1,854,018) (9,220,890) (3,963,752)
Other expense        
Interest and accretion expense (109,689) (173,116) (711)
Share of losses from equity method investment (193,843) (379,633) (472,747)
Total other expense (109,689) (193,843) (552,749) (473,458)
Loss before income taxes (3,232,142) (2,047,861) (9,773,639) (4,437,210)
Income tax benefit 1,702,890 5,844,796
Net loss (1,529,252) (2,047,861) (3,928,843) (4,437,210)
Less: Net loss attributable to noncontrolling interest (58,792) (27,491) (98,485) (63,604)
Net loss attributable to Sanara MedTech shareholders $ (1,470,460) $ (2,020,370) $ (3,830,358) $ (4,373,606)
Net loss per share of common stock, basic and diluted $ (0.18) $ (0.27) $ (0.49) $ (0.60)
Weighted average number of common shares outstanding, basic and diluted 8,107,261 7,518,165 7,836,882 7,279,708